Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Civica Partners With Phlow To Build $125m Injectables Facility In US

Operations Expected To Begin Within Three Years

Executive Summary

Lauding a “dream come true,” Civica has announced plans to build its own injectables manufacturing facility via a strategic partnership with fellow public health firm Phlow Corporation.

You may also be interested in...



Civica’s $27.8m New Facility Expands Virginia Drug Hub Vision

Civica has announced a further $27.8m investment to support its plans for insulin and other essential medicines. The news comes shortly after CivicaScript announced its first launch in the form of abiraterone tablets.

Civica Rx COO McCoy To Step Into CEO Role From 1 June

Civica Rx’s chief operating officer Ned McCoy is to step up as CEO, ahead of the company’s landmark manufacturing facility commencing operations in early 2024.

US Start-Up Phlow Receives Further Capital Injection To Fund Essential Medicines

Fresh from its $812m government contract to help prevent shortages of essential medicines and shield the US market from global competition, domestic start-up Phlow Corporation has received further financial backing.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB150605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel